Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

    NEXT STORY
    Teladoc Health Reports Second Quarter 2019 Results
    PREV STORY
    BioRestorative Therapies Signs $5.4 Million Financing with Institutional Investor
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

    author_avatar
    NASDAQ Market News

    Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates

    author_avatar
    NASDAQ Market News

    SELLAS Life Sciences Announces Review of Strategic Alternatives

    author_avatar
    NASDAQ Market News